drugset / Trial / NCT05664815

Human Amniotic Membrane (hAM) for Stage II Maxillomandibular Osteonecrosis Management

NCT05664815

Phase 2 Recruiting 66 enrolled Centre Hospitalier Universitaire de Besancon
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to demonstrate, during the first standard surgical management of patients with stage II MRONJ, the effect of the implantation of a cryopreserved hAM on the maxillomandibular bone, on the healing of the oral mucosa.

Timeline

Start
2023-09-22
Primary completion
2025-09
Completion
2026-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Human Amniotic Membrane Unknown